No, sorry [Design Issues]

posted by Ohlbe – France, 2024-05-17 15:45 (32 d 22:07 ago) – Posting: # 23999
Views: 1,280

Dear Pharma_88,

Well, olaparib is to be taken every day, twice a day, and has a terminal half-life of 15 hours. How could you possibly do a single-dose BE in patients, without treatment interruption ? Even if you were to enrol patients requiring treatment and who have not started it yet, and do a 72-hour PK after their first dose: that would mean delaying the next doses, which would trigger some ethical concerns, and you would need to go for parallel design.

Regards
Ohlbe

Complete thread:

UA Flag
Activity
 Admin contact
23,058 posts in 4,840 threads, 1,641 registered users;
152 visitors (0 registered, 152 guests [including 11 identified bots]).
Forum time: 13:52 CEST (Europe/Vienna)

Even though it’s applied science we’re
dealin’ with, it still is – science!    Leslie Z. Benet

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5